thalidomide has been researched along with Anemia, Sickle Cell in 12 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
Anemia, Sickle Cell: A disease characterized by chronic hemolytic anemia, episodic painful crises, and pathologic involvement of many organs. It is the clinical expression of homozygosity for hemoglobin S.
Excerpt | Relevance | Reference |
---|---|---|
"Thalidomide alone was also more effective in decreasing H3K27 methylation." | 2.78 | Evaluation of H3 histone methylation and colony formation in erythroid progenitors treated with thalidomide and sodium butyrate. ( Abroun, S; Ahmadvand, M; Chegeni, R; Fard, AD; Hajifathali, A; Kaviani, S; Mohammadi, MM; Noruzinia, M; Saki, N; Soleimani, M; Zonoubi, Z, 2013) |
"Current therapeutic strategies for sickle cell anemia are aimed at reactivating fetal hemoglobin." | 1.43 | Pomalidomide reverses γ-globin silencing through the transcriptional reprogramming of adult hematopoietic progenitors. ( Al-Abed, Y; Allen, SL; An, X; Appiah-Kubi, AO; Blanc, L; Chan, KW; Didier, S; Dulmovits, BM; Gallagher, PG; Gould, M; Hale, J; He, M; Husain-Krautter, S; Lipton, JM; Liu, JM; Marambaud, P; Mohandas, N; Papoin, J; Singh, SA; Taylor, N; Vlachos, A, 2016) |
"Pomalidomide is a potent structural analog of thalidomide and member of a new class of immunomodulatory drugs." | 1.37 | Pomalidomide augments fetal hemoglobin production without the myelosuppressive effects of hydroxyurea in transgenic sickle cell mice. ( Corral, LG; Kutlar, A; Kutlar, F; Meiler, SE; Moutouh-de Parseval, LA; Swerdlow, PS; Wade, M; Xue, Y; Yerigenahally, SD, 2011) |
"Sickle-cell disease (SCD) and beta thalassemia constitute worldwide public health problems." | 1.35 | Pomalidomide and lenalidomide regulate erythropoiesis and fetal hemoglobin production in human CD34+ cells. ( Brady, H; Chan, K; Corral, LG; Ferguson, GD; Glezer, E; Jensen-Pergakes, K; Morris, CL; Moutouh-de Parseval, LA; Muller, G; Verhelle, D, 2008) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 1 (8.33) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 2 (16.67) | 29.6817 |
2010's | 7 (58.33) | 24.3611 |
2020's | 2 (16.67) | 2.80 |
Authors | Studies |
---|---|
Melo, TRF | 1 |
Kumkhaek, C | 1 |
Fernandes, GFDS | 2 |
Lopes Pires, ME | 1 |
Chelucci, RC | 1 |
Barbieri, KP | 1 |
Coelho, F | 1 |
Capote, TSO | 1 |
Lanaro, C | 4 |
Carlos, IZ | 1 |
Marcondes, S | 1 |
Chegaev, K | 1 |
Guglielmo, S | 1 |
Fruttero, R | 1 |
Chung, MC | 2 |
Costa, FF | 4 |
Rodgers, GP | 1 |
Dos Santos, JL | 4 |
Khandros, E | 1 |
Huang, P | 1 |
Peslak, SA | 1 |
Sharma, M | 1 |
Abdulmalik, O | 1 |
Giardine, BM | 1 |
Zhang, Z | 1 |
Keller, CA | 1 |
Hardison, RC | 1 |
Blobel, GA | 1 |
de Melo, TRF | 1 |
Dulmovits, BM | 2 |
de Souza, CM | 1 |
He, M | 2 |
Al Abed, Y | 1 |
Blanc, L | 2 |
Franco-Penteado, CF | 2 |
Silva, FH | 1 |
Fertrin, KY | 1 |
Wade, M | 3 |
Yerigenahally, S | 2 |
de Melo, TR | 1 |
Chin, CM | 1 |
Kutlar, A | 3 |
Meiler, SE | 3 |
Fard, AD | 2 |
Kaviani, S | 2 |
Noruzinia, M | 2 |
Soleimani, M | 1 |
Abroun, S | 1 |
Chegeni, R | 1 |
Hajifathali, A | 1 |
Zonoubi, Z | 1 |
Ahmadvand, M | 1 |
Mohammadi, MM | 1 |
Saki, N | 2 |
Mortaz, E | 1 |
Appiah-Kubi, AO | 1 |
Papoin, J | 1 |
Hale, J | 1 |
Al-Abed, Y | 1 |
Didier, S | 1 |
Gould, M | 1 |
Husain-Krautter, S | 1 |
Singh, SA | 1 |
Chan, KW | 1 |
Vlachos, A | 1 |
Allen, SL | 1 |
Taylor, N | 1 |
Marambaud, P | 1 |
An, X | 1 |
Gallagher, PG | 1 |
Mohandas, N | 1 |
Lipton, JM | 1 |
Liu, JM | 1 |
Kutlar, F | 1 |
Yerigenahally, SD | 1 |
Xue, Y | 1 |
Moutouh-de Parseval, LA | 2 |
Corral, LG | 3 |
Swerdlow, PS | 1 |
Lima, LM | 1 |
Gambero, S | 1 |
Alexandre-Moreira, MS | 1 |
Chung, M | 1 |
Ferguson, GD | 2 |
Jensen-Pergakes, K | 2 |
Wilkey, C | 1 |
Jhaveri, U | 1 |
Richard, N | 1 |
Verhelle, D | 2 |
De Parseval, LM | 1 |
Xie, W | 1 |
Morris, CL | 2 |
Brady, H | 2 |
Chan, K | 2 |
Glezer, E | 1 |
Muller, G | 1 |
Achs, R | 1 |
Harper, RG | 1 |
2 reviews available for thalidomide and Anemia, Sickle Cell
Article | Year |
---|---|
Induction of fetal hemoglobin as a novel therapeutic strategy for β-hemoglobinopathy.
Topics: Anemia, Sickle Cell; Angiogenesis Inhibitors; Animals; beta-Thalassemia; Butyric Acid; Drug Synergis | 2014 |
Dermatoglyphics.
Topics: Abnormalities, Drug-Induced; Anemia, Sickle Cell; Anencephaly; Cerebral Palsy; Chromosome Aberration | 1968 |
1 trial available for thalidomide and Anemia, Sickle Cell
Article | Year |
---|---|
Evaluation of H3 histone methylation and colony formation in erythroid progenitors treated with thalidomide and sodium butyrate.
Topics: AC133 Antigen; Anemia, Sickle Cell; Antigens, CD; beta-Thalassemia; Butyrates; Cells, Cultured; Eryt | 2013 |
9 other studies available for thalidomide and Anemia, Sickle Cell
Article | Year |
---|---|
Discovery of phenylsulfonylfuroxan derivatives as gamma globin inducers by histone acetylation.
Topics: Acetic Acid; Acetylation; Anemia, Sickle Cell; Dose-Response Relationship, Drug; Drug Discovery; gam | 2018 |
Understanding heterogeneity of fetal hemoglobin induction through comparative analysis of F and A erythroblasts.
Topics: Adult; Anemia, Sickle Cell; Cell Line; Cell Separation; Cells, Cultured; Erythroblasts; Erythroid Ce | 2020 |
Synthesis and pharmacological evaluation of pomalidomide derivatives useful for sickle cell disease treatment.
Topics: Anemia, Sickle Cell; Dose-Response Relationship, Drug; Humans; Molecular Structure; Structure-Activi | 2021 |
A thalidomide-hydroxyurea hybrid increases HbF production in sickle cell mice and reduces the release of proinflammatory cytokines in cultured monocytes.
Topics: Anemia, Sickle Cell; Animals; Cytokines; Disease Models, Animal; Fetal Hemoglobin; Hydroxyurea; Infl | 2018 |
Pomalidomide reverses γ-globin silencing through the transcriptional reprogramming of adult hematopoietic progenitors.
Topics: Adult; Anemia, Sickle Cell; beta-Globins; Carrier Proteins; Erythroid Precursor Cells; Erythropoiesi | 2016 |
Pomalidomide augments fetal hemoglobin production without the myelosuppressive effects of hydroxyurea in transgenic sickle cell mice.
Topics: Anemia, Sickle Cell; Animals; Antisickling Agents; Bone Marrow; Disease Models, Animal; Erythropoies | 2011 |
Design, synthesis, and pharmacological evaluation of novel hybrid compounds to treat sickle cell disease symptoms.
Topics: Acetic Acid; Analgesics; Anemia, Sickle Cell; Animals; Anti-Inflammatory Agents; Antisickling Agents | 2011 |
Immunomodulatory drug CC-4047 is a cell-type and stimulus-selective transcriptional inhibitor of cyclooxygenase 2.
Topics: Anemia, Sickle Cell; Anti-Inflammatory Agents, Non-Steroidal; Blotting, Western; Cyclooxygenase 2; C | 2007 |
Pomalidomide and lenalidomide regulate erythropoiesis and fetal hemoglobin production in human CD34+ cells.
Topics: Anemia, Sickle Cell; Antigens, CD34; Antineoplastic Agents; Antisickling Agents; beta-Thalassemia; B | 2008 |